LIGHT THERAPY TREATMENT

• US 20110066213A1
• Filed: 04/30/2010
• Published: 03/17/2011
• Est. Priority Date: 05/01/2009
• Status: Active Grant

• Current Assignee: Wayne State University
• Original Assignee: Wayne State University
• Inventors: Lee, Icksoo, Grossman, Lawrence, Kamholz, John, Huttermann, Maik, Przyklenk, Karin, Sanderson, Thomas
• Granted Patent: US 8,945,196 B2
• Time in Patent Office: Days
• US Class Current: 607/89
• CPC Class Codes: A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissuemeasuring of blood pressure or blood flow A61B5/02; non-radiation detecting or locating of foreign bodies in blood A61B5/06
• CPC Class Codes: A61N 2005/0626 Monitoring, verifying, controlling systems and methods
• CPC Class Codes: A61N 2005/0643 Applicators, probes irradiating specific body areas in close proximity
• CPC Class Codes: A61N 2005/0652 Arrays of diodes
• CPC Class Codes: A61N 2005/0659 infrared
• CPC Class Codes: A61N 5/0613 Apparatus adapted for a specific treatment

Abstract

An exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event. Applying the light to the tissue inhibits cytochrome c oxidase activity. Another exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event and prior to either reoxygenation of the tissue or clinical intervention to reduce cell damage. An exemplary light therapy device includes at least one light source configured to generate light having a wavelength of at least one of approximately 730-770 nm, 850-890 nm, 880-920 nm, and 930-970 nm.

Claims

1. A method comprising:

generating light at a particular wavelength that inhibits cytochrome c oxidase; and

applying the light to organic tissue that has experienced an ischemic event.

2. A method as set forth in claim 1, wherein the light has a spectrum of wavelengths that includes at least one wavelength that inhibits cytochrome c oxidase activity.

3. A method as set forth in claim 1, wherein the light has at least two wavelengths that inhibit cytochrome c oxidase.

4. A method as set forth in claim 1, wherein the light is generated with a power density sufficient to penetrate a human patient'"'"'s tissue.

5. A method as set forth in claim 1, wherein the applying step is initiated no later than the onset of reoxygenation of the organic tissue.

6. A method as set forth in claim 1, wherein the applying step is initiated no later than the onset of a clinical intervention activity.

7. A method as set forth in claim 1, wherein the applying step is initiated no later than the onset of reoxygenation of the organic tissue and continues for at least a subset of the time period during which the organic tissue is being reoxygenated.

8. A method as set forth in claim 1, wherein the applying step is initiated no later than the onset of a clinical intervention activity and continues for at least a subset of the time period during which the organic tissue is being reoxygenated.

9. A light therapy device that generates light having at least one wavelength that inhibits cytochrome c oxidase when applied to organic tissue that has experienced an ischemic event and that has a power density sufficient to penetrate a human patient'"'"'s tissue.

10. A light therapy device as set forth in claim 9, wherein the light has a spectrum of wavelengths that includes at least one wavelength that inhibits cytochrome c oxidase activity.

11. A light therapy device as set forth in claim 9, wherein the light has at least two wavelengths that inhibit cytochrome c oxidase.

12. A light therapy device as set forth in claim 9, wherein the light therapy device generates light having at least one wavelength chosen from the following group:

approximately 730-770 nm, approximately 850-890 nm, approximately 880-920 nm, and approximately 930-970 nm.

13. A method comprising:

generating light having a wavelength of at least one of approximately 730-770 nm, approximately 850-890 nm, approximately 880-920 nm, and approximately 930-970 nm; and

applying the light to organic tissue that has experienced an ischemic event.

14. A method as set forth in claim 13, wherein the light has a wavelength of at least one of approximately 750 nm, 870 nm, 900 nm, and 950 nm.

15. A method as set forth in claim 13, wherein the light has a spectrum of wavelengths that includes at least one wavelength chosen from the following:

approximately 730-770 nm, approximately 850-890 nm, approximately 880-920 nm, and approximately 930-970 nm.

16. A method as set forth in claim 13, wherein the light has at least two wavelengths chosen from the following:

approximately 730-770 nm, approximately 850-890 nm, approximately 880-920 nm, and approximately 930-970 nm.

17. A method as set forth in claim 13, wherein the light is generated with a power density sufficient to penetrate a human patient'"'"'s tissue.

18. A method as set forth in claim 13, wherein the applying step is initiated no later than the onset of reoxygenation of the organic tissue.

19. A method as set forth in claim 13, wherein the applying step is initiated no later than the onset of a clinical intervention activity.

20. A method as set forth in claim 13, wherein the applying step is initiated no later than the onset of reoxygenation of the organic tissue and continues for at least a subset of the time period during which the organic tissue is being reoxygenated.

21. A method as set forth in claim 13, wherein the applying step is initiated no later than the onset of a clinical intervention activity and continues for at least a subset of the time period during which the organic tissue is being reoxygenated.

22. A light therapy device that generates light having a wavelength of at least one of approximately 730-770 nm, approximately 850-890 nm, approximately 880-920 nm, and approximately 930-970 nm and having a power density sufficient to penetrate a human patient'"'"'s tissue.

23. A light therapy device as set forth in claim 22, wherein the light has a wavelength of at least one of approximately 750 nm, approximately 870 nm, approximately 900 nm, and approximately 950 nm.

24. A light therapy device as set forth in claim 22, wherein the light has at least two wavelengths, each of which is selected from the group of approximately 750 nm, approximately 870 nm, approximately 900 nm, and approximately 950 nm.

25. A light therapy device as set forth in claim 22, wherein the light is generated by at least one of a light emitting diode, an optical fiber, and a laser.

26. A method comprising:

generating light at a particular wavelength in the infrared spectrum; and

applying the light to organic tissue that has experienced an ischemic event, wherein application of the light is initiated at a time selected from the following group;

(i) prior to the onset of reoxygenation of the tissue, (ii) at the onset of reoxygenation of the tissue, and (iii) after the onset of and during at least a subset of the time that the tissue is reoxygenated, so as to reduce cell damage caused by reoxygenation of the tissue.

27. A method as set forth in claim 26, wherein application of the light is initiated no later than the onset of reoxygenation and is maintained during at least a subset of the time that the tissue is rexoygenated.

28. A method as set forth in claim 26, wherein the light has a wavelength of at least one of approximately 730-770 nm, 850-890 nm, 880-920 nm, and 930-970 nm.

29. A method as set forth in claim 26, wherein the light has a wavelength of at least one of approximately 750 nm, approximately 870 nm, approximately 900 nm, and approximately 950 nm.

30. A method comprising:

generating light at a particular wavelength in the infrared spectrum;

applying the light to organic tissue that has experienced an ischemic event, wherein application of the light is initiated no later than the onset of a clinical intervention activity intended to result in reoxygenation of the tissue.

31. A method as set forth in claim 30, further comprising maintaining application of the light to the tissue during at least a subset of the time period during which the tissue is being reoxygenated.

32. A method as set forth in claim 30, wherein the light has at least one wavelength chosen from the group of:

approximately 750 nm, approximately 870 nm, approximately 900 nm, and approximately 950 nm.

33. A method as set forth in claim 30, wherein the light has at least two wavelengths, each of which is selected from the group of approximately 750 nm, approximately 870 nm, approximately 900 nm, and approximately 950 nm.

34. A method as set forth in claim 30, wherein the light has at least one wavelength that inhibits cytochrome c oxidase.

35. A method as set forth in claim 30, wherein the light has at least two wavelengths that each inhibits cytochrome c oxidase.